Bli medlem
Bli medlem

Du är här


BioStock: Spago Nanomedical prepares for an eventful 2022

Lund-based Spago Nanomedical has completed the pre-clinical programme with SN201, the candidate drug in the cancer treatment project Tumorad. Reaching this milestone,together with the completion of the second cohort in the SPAGOPIX-01 study, the company ends the year on a high note as it prepares for an eventful 2022. BioStock reached out to CEO Mats Hansen to find out more.

Read the interview with Spago Nanomedical's CEO Mats Hansen at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision